



SCIENTIFIC ARTICLE

Effectiveness of platelet rich plasma in pain management of osteoarthritis knee: double blind, randomized comparative study



Babita Ghai^a, Vasudha Gupta^b, Ashish Jain^c, Nitika Goel ^{a,*}, Devender Chouhan ^e, Yatinder Kumar Batra ^d

^a Post Graduate Institute of Medical education and Research, Department of Anaesthesiology and Intensive Care, Chandigarh, India

^b All India Institute of Medical Sciences, Department of Anaesthesiology, Pain Medicine and Critical Care, New Delhi, India

^c Institute of Medical Education and Research, Department of Transfusion Medicine, Chandigarh, India

^d Max Hospital, Department of Anaesthesia, Mohali, India

^e Post Graduate Institute of Medical Education and Research, Department of Orthopaedics, Chandigarh, India

Received 20 January 2019; accepted 9 June 2019

Available online 14 September 2019

KEYWORDS

Osteoarthritis knee;
Platelet rich plasma;
WOMAC score

Abstract

Background: Intra-articular injections of platelet-rich plasma to treat symptoms of knee osteoarthritis have been successfully used in young patients. However in most of these studies the control and test knees were present in different patients thus incorporating a large amount of bias in the results. Therefore, the present study was designed in which patients with bilateral osteoarthritis knee were included and platelet-rich plasma was administered in one knee and normal saline in another knee of same patient.

Methods: 20 patients aged 30–65 years with bilateral osteoarthritis knees (ASA class I and II) of either gender were included in the study. Patients were randomized to receive platelet-rich plasma and normal saline in one of the two knees. The primary outcome was VAS and WOMAC score at 6 months after procedure. The secondary outcome included changes in joint stiffness, physical function, any adverse effects noted during the course of study.

Results: The baseline VAS score in platelet-rich plasma knee was 8.4 ± 0.88 which improved significantly to 4.85 ± 2.48 ($p < 0.001$) at 6 months as compared to normal saline knee ($p = 0.017$). The WOMAC pain score also improved from baseline (14.5 ± 1.3) to over 6 month 7.00 ± 4.24 ($p < 0.001$) in platelet-rich plasma knee while in the normal saline knee, no significant change occurred from baseline to six months (10.2 ± 1.2 to 10.05 ± 1.23). There was also significant decrease in stiffness and improvement of physical activity in the platelet-rich plasma knee as compared to normal saline knee.

* Corresponding author.

E-mail: nitikagoel7@gmail.com (N. Goel).

Conclusion: The present study showed significant decrease in pain and stiffness and improvement of physical functions of knee joint with intra-articular platelet-rich plasma injection as compared to normal saline.

© 2019 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALAVRAS-CHAVE

Osteoartrite de joelho;
Plasma rico em plaquetas;
Escore WOMAC

Efetividade do plasma rico em plaquetas no tratamento da dor em osteoartrite de joelho: estudo comparativo randômico e duplo-cego

Resumo

Justificativa e objetivos: Injeções intra-articulares de plasma rico em plaquetas têm sido usadas com sucesso para tratar os sintomas da osteoartrite de joelho em pacientes jovens. Porém, na maioria desses estudos, os joelhos de controle e teste estavam presentes em diferentes pacientes, o que incorporou uma grande quantidade de viés aos resultados. Portanto, o projeto do presente estudo incluiu pacientes com osteoartrite em ambos os joelhos, com a administração de plasma rico em plaquetas em um dos joelhos e de solução salina normal no outro joelho do mesmo paciente.

Métodos: 20 pacientes, de ambos os sexos, com idades entre 30–65 anos e portadores de osteoartrite bilateral de joelho (classificação ASA I e II) foram incluídos no estudo. Os pacientes foram randomizados para receber plasma rico em plaquetas e solução salina normal em um dos dois joelhos. O desfecho primário foram os escores VAS e WOMAC seis meses após o procedimento. O desfecho secundário incluiu alterações na rigidez articular, função física e qualquer efeito adverso observado durante o curso do estudo.

Resultados: O escore VAS basal para o joelho que recebeu plasma rico em plaquetas foi $8,4 \pm 0,88$ e melhorou significativamente para $4,85 \pm 2,48$ ($p < 0,001$) após seis meses, comparado ao joelho que recebeu solução salina normal ($p = 0,017$). A intensidade da dor avaliada com o WOMAC também melhorou de $14,5 \pm 1,3$ na fase basal para $7,00 \pm 4,24$ após seis meses ($p < 0,001$) nos joelhos que receberam plasma rico em plaquetas, enquanto nenhuma mudança significativa ocorreu nos joelhos que receberam solução salina normal entre a fase basal e após seis meses ($10,2 \pm 1,2$ a $10,05 \pm 1,23$). Além disso, houve uma diminuição significativa da rigidez e melhora da atividade física nos joelhos que receberam plasma rico em plaquetas, comparados aos joelhos que receberam salina normal.

Conclusão: O presente estudo identificou uma diminuição significativa da dor e da rigidez e uma melhora das funções físicas da articulação do joelho com a injeção intra-articular de plasma rico em plaquetas, comparada à solução salina normal.

© 2019 Sociedade Brasileira de Anestesiologia. Publicado por Elsevier Editora Ltda. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Osteoarthritis (OA) is the most common chronic joint disorder, and it causes detrimental effects on the quality of life and functional status.¹ The proportions of people affected with symptomatic knee OA is likely to increase with increasing rate of obesity in the general population.² Several methods are used for alleviating the pain of patients with knee OA, which includes medications and supplements (NSAIDs, glucosamine and chondroitin sulfate), intra-articular injections (glucocorticoids, hyaluronic acid), physical agents (braces, shoes and insoles, exercise therapy, application of cold and heat modalities, etc.) and surgical intervention.³⁻⁵ Since osteoarthritis alters the normal joint metabolism and decreases anabolism, the administration of Platelet Rich Plasma (PRP) containing

numerous growth factors such as Hepatocyte Growth Factors (HGF), Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF) and Transforming Growth Factor (TGF) has been known to alter joint milieu in OA.⁶

Various studies have found positive results for Platelet Rich Plasma (PRP) in early Osteoarthritis (OA) knee in the past few years.¹ However most of these studies had moderate to high degree of bias in their results. Therefore the present study was planned which included patients of bilateral OA knee (Grade 1 and 2) where PRP was administered in one knee and normal saline in another knee of same patient. The same patient served as both test and control. Such a study was expected to nullify a great number of confounding factors while keeping the baseline characteristics same as regard to BMI, height, weight, ASA class and thus elimi-

nate the chance of selection bias and observer bias in the results.

Methodology

This was a single center, double blind, randomized comparative study conducted at one of the tertiary care center. Study was conducted in accordance to the principles of Declaration of Helsinki. Institute ethics committee approval and written informed consent from all patients was obtained. Patients were recruited from pain clinic referred from orthopedic OPD (PGIMER, Chandigarh).

Inclusion and exclusion criteria

Patients aged 30–65 years with bilateral OA knees (ASA class I and II) of either gender, with history of pain or swelling in the knee >4 months, those with imaging findings (X-ray or MRI) of degenerative changes of the joint without significant deformity (diagnosed by KL classification (Grade 1 and 2)) were included in this study.

Patients with history of diabetes mellitus, immunosuppressive drugs, collagen vascular disorders, cancer or malignant disorders and those with or active infection/wound of the knee were excluded. Also, patients with autoimmune and platelet disorders, treatment with anticoagulant and antiplatelet medications 10 days before injection or use of NSAIDs 2 days before injection or history of knee articular injection of corticosteroid during previous 3 months or use of systemic corticosteroids 2 weeks before PRP injection were excluded. Patients with genu valgum/varum greater than 20 degrees and Human Immunocompromised Virus/Hepatitis B virus/Hepatitis C virus/Venereal Disease Research Laboratory virus positive cases were also excluded.

Patient randomization and blinding

The knees were randomly allocated into two groups with the use of a computer generated random number table. The random numbers were kept in opaque envelopes, numbered sequentially and each envelope was opened just prior to the starting of the procedure. They were assigned into either of the two groups: Knee (P), it included the knee receiving 8mL of platelet rich plasma; Knee (N), it included the knee receiving 8mL of normal saline as control knee.

There was a gap of 30 min between the injections in two knees. One investigator performed all the knee injections (VG). The patient and investigators collecting the data were unaware of which knee got what treatment.

Interventional procedure

The patient was placed in a supine position. Under aseptic conditions, ultrasound guided 8mL of either normal saline or platelet concentrate was injected into a

supra-patellar pouch through a supra lateral approach with an 18 gauge needle. In the knee receiving PRP, 2mL of CaCl₂ (M/40) was injected and sham on other knee. The knees were immobilized for 10 min after injection. Data collected included baseline VAS (Visual Analog Scale) score and WOMAC scoring (Western Ontario and McMaster Universities Osteoarthritis Index) by an independent observer in each knee.

Co-interventions and post-intervention medications

Patient lied down in supine position for 2 h and monitored for HR, BP, SPO₂ and any adverse events. All participants were receiving conservative management (adjuvant drugs: NSAIDs and/or a therapeutic exercise program) before joining the study. They were instructed to stop all the pain medication 2 days prior to the injection and thereafter. Participants who showed substantial improvement with the study intervention reduced or stopped their drugs; for the other patients, dosages were increased or continued at the same dosages. Acetaminophen 500 mg was advised as first line rescue analgesia and oral tramadol as second rescue analgesia if required. Exercises and job attendance continued. No other additional treatments, such as physical therapy (ultrasound therapy, microwave diathermy, moist heat) or other interventions, other than the assigned study intervention was offered.

Primary and secondary outcomes

We defined the approach as "effective" when pain relief was ≥50% from baseline. The primary outcomes of the study were the percentage change in Visual Analog Score (VAS) at 6 months following the procedure. The secondary outcomes included changes in Western Ontario and McMaster osteoarthritis index (WOMAC) scores, joint stiffness, physical function, any adverse effects noted during the course of study. The nature, time of onset, duration, severity and relationship of the adverse effect to treatment were noted at each visit.

Follow-up

Patients were evaluated on the day of injection, 2 weeks, 1.5 month, 3 months and 6 months by a blinded observer for intensity of pain in VAS and WOMAC score. Any adverse event reported by the patient during the study was recorded at each visit.

PRP preparation

The platelet rich plasma required for injection was prepared on the day of the intervention procedure and was provided by the department of transfusion medicine, PGIMER, Chandigarh. About 50–60mL of blood was drawn from the antecubital vein of the patient using aseptic precautions




Figure 1 Flowchart of patients in this study (no losses in follow up).

with efforts to avoid irritation and trauma to the platelets, which are in a resting state. The blood was collected in a blood bag (Terumo Penpol Ltd., Thiruvananthapuram, Kerala, India) with Citrate Phosphate Dextrose and Adenine (CDPA1) as anticoagulant preservative solution. These blood bags had 49 mL of anticoagulant and also contained an empty satellite bag connected with the primary bag through an internal seal. Before collecting the patient's blood, 40 mL of CDPA1 was diverted to the satellite bag from the primary bag and the connecting tubing was sealed using a portable tube sealer (Terumo Penpol Ltd., Thiruvananthapuram, Kerala, India). Thus the primary bag in which the patient's blood was collected contained 9 mL of CDPA1 sufficient to provide anticoagulation for 50–60 mL patient's blood. The whole blood was then transferred from the blood bag into sterile tubes (Tarsons, India) using a blood transfusion set, inside a biosafety cabinet, class IIA (BIOAIR Safe flow 1.2, Euroclone, Siziano, Italy). These tubes were then centrifuged for 15 min at 1300 rpm inside a tabletop centrifuge. The whole blood was separated into Platelet Rich

Plasma (PRP) and Residual Blood Cell (RBCs) with the buffy coat. The tubes were then again brought inside the biosafety cabinet. The PRP was pipetted and transferred to another sterile tube. It was again subjected to a second centrifugation for 5 min at 2200 rpm inside a tabletop centrifuge. After this the supernatant platelet poor plasma was pipetted inside the biosafety cabinet into another tube so as to leave behind 8–10 mL along with the platelet pellet at the bottom. The platelet pellet was then re-suspended in the remaining plasma as the final PRP and was dispensed in a sterile syringe; 1 mL of calcium chloride (CaCl_2) (M/40) for every 4 mL of final PRP was also dispensed in a separate syringe for injection with the final PRP. The platelet count of patient's peripheral blood as well as the final PRP was also done using a hematology analyser (Orion 60, Ocean Medical Technologies, New Delhi, India). The mean platelet count achieved by our method was $310.14 \times 10^3/\text{mL}$, and the mean quantity of platelets injected per knee was 238.56×10^7 . The product is type 4B as per the Mishra classification.⁷

Table 1 Demographic characteristics of study population.

Age (yrs)	49.8 ± 9.42
Gender (%)	75% female; 25% male
Weight (kg)	67 ± 9.56
ASA status (%)	80% ASA I; 20% ASA 2
Hemoglobin (g.dL ⁻¹)	11.5 ± 1.26
Platelet count ($\times 10^9 \cdot L^{-1}$)	227.25 ± 9.40
Total leukocyte count ($\cdot L^{-1}$)	5130 ± 939

Values are presented as mean ± standard deviation or percentage.

Statistical analysis

Data are presented as mean ± SD. Data were analyzed for normality using Kolmogorov-Smirnov Z test. Demographic data were analyzed using Student "t" test or χ^2 test. Categorical data including primary endpoint were analyzed by χ^2 test. Two-way repeated measures analysis of variance was conducted to analyze VAS and WOMAC score over time. For this, the data were tested for normality, homogeneity, and equal covariance by Kolmogorov-Smirnov Z test, Levene test for equality of error variances, and Box Test of Equality of Covariance Matrices, respectively. The assumption of sphericity was tested by Mauchly test. If the Mauchly

test was significant indicating violation of the assumption of sphericity, we used the Greenhouse-Geisser test with adjustment for time × factor, time × group interaction and between subject effects for VAS and WOMAC. If found significant, follow-up analysis was performed with Bonferroni correction for multiple comparisons. Computer statistical software SPSS version 17.0 (SPSS Inc., Chicago, IL) was used for analysis; $p < 0.05$ was considered significant.

Sample size calculation

Our sample size was based upon an assumed study power of 80%, α of 0.05, and expecting a minimum of 50% decrease in the VAS score in the treatment group (difference of standard deviation = 2.5). Using these parameters, we required approximately 10 patients per treatment arm.

Results

Total 40 patients were screened for eligibility criteria (Fig. 1); 25 met inclusion criteria, out of which 5 patients did not give consent for the procedure. Therefore a total of 20 patients with bilateral early osteoarthritis knee were selected on the basis of pre-defined inclusion criteria after written informed consent. Demographic

Table 2 The VAS and WOMAC score at different time intervals.

Treated group	Follow-up	VAS	WOMAC (Total)	WOMAC (Pain)	WOMAC (Stiffness)	WOMAC (Daily physical activity)
PRP group	Baseline	8.40 ± 0.883	37.5 ± 3	14.15 ± 1.3	5.5 ± 0.8	17.7 ± 1.34
	Just after injection	8.30 ± 0.979	36.9 ± 3.1	13.75 ± 1.2	5.5 ± 0.9	17.7 ± 1.34
	2 week	7.10 ± 1.4	27.75 ± 27.75	10.65 ± 1.72	4.2 ± 0.6	12.9 ± 2.2
		$p = 0.005$	$p < 0.001$	$p = 0.005$	$p = 0.00$	$p = 0.00$
	1.5 month	5.95 ± 1.8	27.75 ± 4.75	10.60 ± 1.6	4.2 ± 0.8	12.9 ± 2.2
		$p = 0.001$	$p < 0.001$	$p = 0.005$	$p = 0.00$	$p = 0.00$
	3 month	5.0 ± 2.3	18.0 ± 9.6	6.9 ± 3.68	2.7 ± 1.5	8.4 ± 4.5
		$p < 0.001$	$p < 0.001$	$p < 0.001$	$p = 0.00$	$p = 0.00$
NS group	6 month	4.85 ± 2.48	18.1 ± 11	7 ± 4.24	2.7 ± 1.5	8.4 ± 5.3
		$p < 0.001$	$p < 0.001$	$p < 0.001$	$p = 0.00$	$p = 0.00$
	Baseline	7.15 ± 0.93	26.65 ± 2.9	10.2 ± 1.2	4.1 ± 0.45	12.3 ± 1.34
	Just after injection	7.2 ± 0.95	26.65 ± 2.9	10.25 ± 1.11	4.1 ± 0.45	12.3 ± 1.34
	2 week	7.15 ± 0.93	26.75 ± 2.9	10.35 ± 1.13	4.1 ± 0.45	12.3 ± 1.34
		$p = 0.317$	$p = 1.00$	$p = 1.00$	$p = 1.00$	$p = 1.00$
	1.5 month	7.15 ± 0.93	26.75 ± 2.9	10.35 ± 1.11	4.1 ± 0.45	12.3 ± 1.34
		$p = 1.00$	$p = 0.157$	$p = 0.157$	$p = 1.00$	$p = 1.00$
	3 month	7.15 ± 0.93	26.65 ± 2.9	10.35 ± 1.11	4.1 ± 0.45	12.3 ± 1.34
		$p = 1.00$	$p = 1.00$	$p = 1.00$	$p = 1.00$	$p = 1.00$
	6 month	5.7 ± 2.9	26.45 ± 2.9	10.05 ± 1.23	4.1 ± 0.45	12.3 ± 1.34
		$p = 0.017$	$p = 0.046$	$p = 0.046$	$p = 1.00$	$p = 1.00$

Values are presented as mean ± standard deviation.

VAS, Visual Analog Scale; WOMAC, Western Ontario and McMaster osteoarthritis index.




Figure 2 Percentage change in VAS score from baseline. VAS- Visual Analogue Scale.




Figure 3 Percentage change in WOMAC (pain) score from baseline. WOMAC- Western Ontario and McMaster osteoarthritis index.

characteristics of study population are presented in [Table 1](#).

Pain parameter in VAS and WOMAC score

Between-knee analysis revealed that VAS and WOMAC pain scores were significantly lower in the PRP knee compared with the NS knee at different time intervals except baseline ([Table 2](#)). Follow up within group analysis also revealed significant decrease in VAS and WOMAC score at all time intervals compared to baseline in the PRP knee ([Figs. 2 and 3](#)). Results of repeated measures analysis of variance revealed time \times factor ($p < 0.001$ for both VAS and WOMAC) and time \times group interaction ($p < 0.001$ for VAS and $p < 0.001$ for WOMAC). Between-knee effect was also significant ($p = 0.001$ for VAS and $p = 0.001$ for WOMAC).

Analysis of trend in overall stiffness

WOMAC score for stiffness was analyzed on 2 aspects (morning and day time stiffness). Each aspect was given




Figure 4 Percentage change in WOMAC (stiffness) from baseline. WOMAC- Western Ontario and McMaster osteoarthritis index.

a score between 0 and 4 and value of each of them was added up. The result was presented as overall score out of 8. Between-group analysis revealed significant decrease in stiffness in the PRP knee compared with the NS knee at different time intervals except baseline ([Table 2](#) and [Fig. 4](#)). Results of repeated measures analysis of variance revealed time \times factor ($p < 0.001$ for overall stiffness).

Analysis of trend in overall daily physical activity

WOMAC score for difficulty in daily physical activity was analyzed on 6 aspects (going downstairs, going upstairs, getting up from sitting position, standing, bending to floor and walking on flat surface). Each aspect was given a score between 0 and 4 and the value of each of them was added up. The result was presented as overall score out of 24. Between-group analysis revealed significant decrease in stiffness in the PRP knee compared with the NS Knee at different time intervals except baseline ([Table 2](#) and [Fig. 4](#)). Results of repeated measures analysis of variance revealed time \times factor ($p < 0.001$ for daily physical activities) ([Fig. 5](#)).

Analysis of trend change in total WOMAC score

WOMAC score for each aspect was added up and result was presented as overall score out of 52 ([Table 2](#)). In PRP knee, there was gradual reduction in total WOMAC score ranging from 1% (immediately post injection), to 25% at 2nd week which persisted up to 1.5th month. There was further improvement at 3rd and 6th month which was about 51%. In NS knee, there was 30% decrease in overall score at end of 6th month ([Fig. 6](#)).

Satisfaction level

For PRP knee 70% were satisfied with treatment, 10% were partially satisfied and 20% were not satisfied. While




Figure 5 Percentage change in WOMAC (physical activity) from baseline.




Figure 6 Percentage change in overall WOMAC score from baseline.

Table 3 Comparison of patient's level of satisfaction with treatment received.

		Group	
		PRP	NS
Satisfaction	Not satisfied	Count	4
		% Within group	20%
	Partially satisfied	Count	2
		% Within group	10%
	Satisfied	Count	14
		% Within group	70%
Total		Count	20
		% Within group	100%

Values are expressed as absolute numbers or percentage.

for NS knee, only 10% were satisfied and 90% unsatisfied ($p=0.001$) (Table 3).

Complications

One patient in PRP knee group developed severe inflammation, swelling and stiffness immediately post injection.

It persisted for 2 weeks after which the pain and stiffness improved. No significant adverse effect was seen in NS group.

Discussion

This is a double blinded randomized controlled study where the same patient has been taken as test as well as control group. We selected patients of bilateral early osteoarthritis knee where we injected PRP in one knee and normal saline in other knee serving as physiological control. To the best of our knowledge this is first study of its kind where same patient has been used as control as well as study group. This eliminates a lot of confounding variables related to individual patient.

Our study showed decrease in mean pain score after 2 weeks of injection in PRP knee. Pain relief was 24% and 50% at 2nd week and 3rd month respectively. In NS knee, no improvement of pain was seen in VAS scale at 2nd week, 1.5th month and 3rd month. At 6 months, pain reduction in PRP knee was 49%, as compared to only 21% decrease in NS knee.

Intra-articular injection of autologous PRP has been considered as one of the treatment option in OA knee. Most of the studies on autologous PRP injection has been focusing on the reduction of pain and improvement of quality of life. Patel et al. performed a randomized control trial in 78 patients with OA knee.⁸ Patients were divided randomly into 3 groups where 1st group received a single injection of PRP, the 2nd group received 2 PRP injections 3 weeks apart and 3rd group received a single injection of NS. Clinical outcome evaluated using WOMAC questionnaire. Statistically significant improvement seen in all WOMAC parameters in the 1st and 2nd group within 2–3 weeks and lasted up to the final follow up at 6 month. In the NS group, the mean WOMAC score deteriorated from the baseline to final follow-up. Their study also showed similar VAS scores in patients receiving either one or more PRP injections. Therefore we have employed only single PRP injection in test knees.

Sampson et al., in their pilot study of 13 patients also showed improvement in pain and daily physical activity on the scales of Knee Injury and Osteoarthritis Outcome Scores (KOOS) with intra-articular PRP injection. Their study lacked a control group.⁹

Wang et al. also showed improvement with intra-articular PRP on VAS, SF-36, WOMAC and Lequesne index. Their study also lacked a control group.¹⁰ Filardo et al. showed positive effects in IKDC and VAS score at the end of their 2 year follow-up study.⁴ Their study also lacked a control group.

PRP has also been compared with other modalities of treatment like HA and TENS. Sanchez et al. performed a retrospective cohort study comparing intra-articular PRGF and HA and reported better improvement in pain and quality of life with PRGF injection.¹¹ However their study was not randomized and lacked blinding of control groups.

Kon et al. compared intra-articular PRP injection with low and high molecular weight hyaluronic acid (HA).¹² Evaluation was done with IKDC and VAS score. They found better results with PRP injection as compared to HA. However their study failed to use a randomized double-blinded method. Our PRP preparation technique was standardized by our transfusion medicine department, and no commercial filters were used. We were able to get a standardized leukocyte-free concentration of platelets for all cases, and per the Mishra classification,⁷ this was Type 4B. The number of platelets injected in our series was an average of 2.5 billion compared with 6.5 million used by Kon et al.¹² (almost 400 times higher).

Raeissadat et al. evaluated WOMAC and SF36 questionnaires in PRP and HA group. They found better results with PRP at 12 month follow up.¹³ Angoorani et al. did a comparative study between intra-articular PRP and TENS plus exercise in 54 patients. Though significant reductions in VAS scores were found in both groups till the end of study, the mean time to feel intolerable knee pain during treadmill work out of PRP group increased significantly from baseline.¹⁴ Jubert et al. have tested the efficacy of intra-articular PRP injection in late stages of OA knee (KL Grade 3 and 4) and reported no statistically significant result with PRP compared to intra-articular corticosteroid injection.¹⁵

Literature reports numerous systemic reviews and meta-analysis describing improved efficacy of PRP compared from hyaluronic acid, corticosteroids and normal saline.^{16–20} Most of randomized controlled trials recruited in these systemic reviews reported moderate to high degree of bias. Our study also demonstrated similar results, but since one patient acted as both study and control, confounding variables related to the individual patient were removed. However our study should be read in light of few limitations which may be brought out for the benefit of researchers planning similar studies in future. In our study same patient received different treatment in his two knees, which made the procedure cumbersome. Though we could assess for WOMAC pain and stiffness separately for each knee, assessment of physical activity of each knee separately may have been affected by pathology in another knee. Moreover our follow up duration was 6 months which is not enough for adequately evaluating a chronic condition like OA knee. We evaluated only clinical parameters by using WOMAC and VAS scoring system. No radiographic follow up was done. Our study included only early OA knee with KL Grade 1 and 2. So results cannot be applicable to KL Grade 3 and 4.

The present study showed significant improvement in pain, stiffness and physical functions of knee joint with intra-articular PRP injection as compared to NS. The greatest strength of our study is that same patient served as control as well test knee. Though one patient developed pain and inflammatory swelling following PRP injection, it is difficult to determine exact relation between occurrence of complications and PRP administration. Therefore we recommend judicious administration of PRP for OA knee.

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Kavadar G, Demircioglu DT, Celik MY, et al. Effectiveness of platelet-rich plasma in the treatment of moderate knee osteoarthritis: a randomized prospective study. *J Phys Ther Sci.* 2015;27:3863–7.
2. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. *Clin Geriatr Med.* 2010;26:355–69.
3. Crane D, Everts P. Platelet Rich Plasma (PRP) matrix grafts. *Pract Pain Manage.* 2008;8:12–26.
4. Filardo G, Kon E, Buda R, et al. Platelet rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. *Knee Surg Sports Traumatol Arthrosc.* 2011;19:528–35.
5. Kon E, Buda R, Filardo G. Platelet rich plasma: intra-articular knee injections produced favourable results on degenerative cartilage lesions. *Knee Surg Sports Traumatol Arthrosc.* 2011;18:427–79.
6. Boswell SG, Cole BJ, Sundman EA, et al. Platelet rich plasma: a milieu of bioactive factors. *Arthroscopy.* 2012;28:429–39.
7. Mishra A, Harmon K, Woodall J, et al. Sports medicine applications of platelet rich plasma. *Curr Pharm Biotechnol.* 2012;13:1185–95.
8. Patel S, Dhillon MS, Aggarwal S, et al. Treatment with Platelet rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double blind, randomized trial. *Am J Sports Med.* 2013;41:356–64.
9. Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. *Ethics Sci Environ Politics.* 2008;1:165–74.
10. Wang-Saegusa A, Cugat R, Ares O, et al. Infiltration of plasma rich in growth factors for osteoarthritis of the knee short term effects on function and quality of life. *Arch Orthopand Trauma Surg.* 2011;131:311–7.
11. Sanchez M, Anita E, Azofra J, et al. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study. *Clin Exp Rheumatol.* 2008;26:910–3.
12. Kon E, Buda R, Filardo G. Platelet rich plasma: intra-articular knee injections produced favourable results on degenerative cartilage lesions. *Knee Surg Sports Traumatol Arthrosc.* 2010;18:472–9.
13. Raeissadat SA, Rayegani SM, Ghorbani E. The effect of platelet-rich plasma on pain, Pneumology Dept, Hospital San Pedro de Alcántara, Cáceres, Spain. *Pain Res Treat.* 2013:165–967.
14. Angoorani H, Mazeherinezhad A, Marjomaki O, et al. Treatment of knee osteoarthritis with platelet rich plasma in comparison with transcutaneous electrical nerve stimulation plus exercise: a randomized clinical trial. *Med J Islam Repub Iran.* 2015;27:223.
15. Joshi Jubert N, Rodríguez L, Reverté-Vinaixa MM, et al. Platelet-rich plasma injections for advanced knee osteoarthritis: a prospective, randomized, double-blinded clinical trial. *Orthop J Sports Med.* 2017;13:5.
16. Fotouhi A, Maleki A, Dolati S, et al. Platelet rich plasma, stromal vascular fraction and autologous conditioned serum in treatment of knee osteoarthritis. *Biomed Pharmacother.* 2018;104:652–60.

17. Shen L, Yuan T, Chen S, et al. The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials. *J Orthop Surg Res.* 2017;23:12.
18. Dai WL, Zhou AG, Zhang H, et al. Efficacy of platelet-rich plasma in the treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials. *Arthroscopy.* 2017;33:659–70.
19. Meheux CJ, McCulloch PC, Lintner DM, et al. Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. *Arthroscopy.* 2016;32:495–505.
20. Lai LP, Stitik TP, Foye PM, et al. use of platelet-rich plasma in intra-articular knee injections for osteoarthritis: a systematic review. *PM R.* 2015;7:637–48.